GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (FRA:RGN) » Definitions » Total Long-Term Liabilities

Repligen (FRA:RGN) Total Long-Term Liabilities : €661.1 Mil (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Repligen Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Repligen's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was €661.1 Mil.

Repligen Total Long-Term Liabilities Historical Data

The historical data trend for Repligen's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Total Long-Term Liabilities Chart

Repligen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.03 206.23 204.57 643.18 697.30

Repligen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 644.33 651.47 635.74 697.30 661.06

Repligen Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Repligen Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Repligen's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Repligen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (FRA:RGN) » Definitions » Total Long-Term Liabilities
Comparable Companies
STVN MMSI TFX AVTR ICUI XRAY ATR NVST WRBY LMAT ISRG XPAR:EL BDX TSE:7741 XSWX:ALC RMD TSE:4543 OCSE:COLO B XPAR:DIM XSWX:STMN
Traded in Other Exchanges
RGEN:USA RGN:Germany
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Website
https://www.repligen.com
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Repligen Headlines

No Headlines